United Therapeutics Corp
Veridion Score
Composite trend over time
Why is UTHR moving today?
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for UTHR.
UTHR insider activity
United Therapeutics Corp
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for UTHR.
UTHR contract awards, year to date.
Public federal awards linked to this ticker.
UTHR lobbying filings, year to date.
Registered lobbying filings matched to United Therapeutics Corp.